Cancer Therapy pp 225-230 | Cite as

CNS and Cardiovascular Effects of TNF-α

  • F. Squadrito
  • A. P. Caputi
Conference paper
Part of the NATO ASI Series book series (volume 75)


Recombinant cytokines have high potential for modulating immunity in cancer, viral illness and immunodeficient states. However their large use in clinical trials turned out to be impraticable because of severe systemic side-effects (Chouaib et al., 1992). The cardiovascular system and Central Nervous System (CNS) represent the main targets of Tumor Necrosis Factor (TNF-α) toxicity. Experimental studies have confirmed that systemic or intracerebral injection of recombinant TNF-α has profound cardiovascular and neurological effects in addition to its pyrogenic and metabolic activity. Understanding and elucidating the mechanisms underlying cardiovascular and CNS toxicity should enable the design of molecules to oppose this toxicity without interfering with the immune reactions.


Nitric Oxide Platelet Activate Factor Drinking Behavior Central Nervous System Toxicity Recombinant Cytokine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Butcher EC (1990) Cellular and molecular mechanisms that direct leukocyte traffic. Am J Pathol 136: 3–11.PubMedGoogle Scholar
  2. Calapai G, Squadrito F, Massi M, Caputi AP, de Caro G (1990) Endotoxin inhibition of drinking behavior in the rat. Pharmacol Res 22: 161–170Google Scholar
  3. Calapai G, Squadrito F, Altavilla D, Zingarelli B, Campo GM, Cilia M, Caputi AP (1992) Evidence that nitric oxide modulates drinking behavior. Neurophamacol 31: 761–764.CrossRefGoogle Scholar
  4. Caputi AP, Squadrito F (1992) Role of TNF-α and therapeutic perspectives in the model of bowel and myocardial ischaemia/reperfusion injury. Pharmacol Ress 26 (suppl 2): 150–151.CrossRefGoogle Scholar
  5. Comstock LE, Thomas DD (1989) Penetration of endothelial cells monolayers by Borrelia burgdorferi. Infect Immun 57: 1626–1628.PubMedGoogle Scholar
  6. Chouaib S, Branellec D, Buurman WA (1991) More insights into the complex physiology of TNF. Immunol Today 12: 141–142.PubMedGoogle Scholar
  7. Cunnion RE, Parrillo JE (1989) Myocardial dysfunction in sepsis. Crit Care Clin 5: 99–118.PubMedGoogle Scholar
  8. Fuller LM (1984) Hie pharmacology of drinking behavior. Pharmacol Ther 24: 179–206PubMedCrossRefGoogle Scholar
  9. Grossman SP (ed) (1990) Thirst and Sodium appetite. Physiological basis. Academic Press San DiegoGoogle Scholar
  10. Gulick T, Chung MK, Pieper SJ, Lange LG, Screiner GF (1989) Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad sci USA 86: 6753–6757.PubMedCrossRefGoogle Scholar
  11. Kent S, Bluthe’ R, Kelley KW, Dantzer R (1992) Sickness behavior as a new target for drug development. Tips 13: 23–28.Google Scholar
  12. Kettelhut IC, Fiers W, Goldeberg L (1987) The toxic effect of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 84: 4273–4277.PubMedCrossRefGoogle Scholar
  13. Knoweles RG, Palacios M, Plamer RM, Moncada S (1990) Kinetic characteristics of nitric oxide from rat brain. Biochem J 269: 207–210Google Scholar
  14. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in in severe chronic heart failure. N Engl J Med 323: 236–240.PubMedCrossRefGoogle Scholar
  15. Mantovani A, Dejana E (1989) Cytokines as communication signal between leukocytes and endothelial cells. Immunol Today 10: 370–375.PubMedCrossRefGoogle Scholar
  16. Murphy S, Minor RL, Welk G, Harrison DG (1990) Evidence for an astrocyte-derived vasorelaxing factor with properties similar to nitric oxide. J Neurochem 55: 349–351.PubMedCrossRefGoogle Scholar
  17. Osborn L (1990) Leukocyte adhesion to endothelium in inflammation. Cell 62: 48–51.CrossRefGoogle Scholar
  18. Plata-Salaman CR (1988) Food intake suppression by immunomodulators. Neurosci Res Comm 3: 159–165.Google Scholar
  19. Rola-Pleszczyshi M, Bosse J, Bissonnette E, Dubois C (1988) PAF acether enhances the production of tumor necrosis factor by human and rodent lymphocytes and macrophages. Prostaglandins 35: 802–806.CrossRefGoogle Scholar
  20. Squadrito F, Sturniolo R, Altavilla D, Santoro G, Campo GM, Arena A, Caputi AP (1991) Platelet activating factor involvement in splanchnic artery occlusion shock. Eur J Pharmacol 192: 47–50.PubMedCrossRefGoogle Scholar
  21. Squadrito F, Calapai G, Zingarelli B, Altavilla D, Campo GM, Caputi AP (1992) Evidence for a role of nitric oxide in the endotoxin inhibition of drinking behavior in the rat. In: Moncada S, Marletta MA, Hibbs JB, Higgs RA (eds) The biology of nitric oxide I Portland Press London, 276.Google Scholar
  22. Vilcek J, Lee TH (1991) Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem 266: 7313–7316.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • F. Squadrito
    • 1
  • A. P. Caputi
    • 1
  1. 1.Institute of Pharmacology, School of MedicineUniversity of MessinaMessinaItaly

Personalised recommendations